136 related articles for article (PubMed ID: 18585508)
1. One-year clinical outcome after abciximab bolus-only compared with abciximab bolus and 12-hour infusion in the Randomized EArly Discharge after Transradial Stenting of CoronarY Arteries (EASY) Study.
Bertrand OF; Rodés-Cabau J; Larose E; Nguyen CM; Roy L; Déry JP; Courtis J; Nault I; Poirier P; Costerousse O; De Larochellière R
Am Heart J; 2008 Jul; 156(1):135-40. PubMed ID: 18585508
[TBL] [Abstract][Full Text] [Related]
2. Long term efficacy of abciximab bolus-only compared to abciximab bolus and infusion after transradial coronary stenting.
Bagur R; Bertrand OF; Rodés-Cabau J; Larose E; Rinfret S; Nguyen CM; Noel B; Larochellière RD; Poirier P; Costerousse O; Roy L
Catheter Cardiovasc Interv; 2009 Dec; 74(7):1010-6. PubMed ID: 19753635
[TBL] [Abstract][Full Text] [Related]
3. A randomized study comparing same-day home discharge and abciximab bolus only to overnight hospitalization and abciximab bolus and infusion after transradial coronary stent implantation.
Bertrand OF; De Larochellière R; Rodés-Cabau J; Proulx G; Gleeton O; Nguyen CM; Déry JP; Barbeau G; Noël B; Larose E; Poirier P; Roy L;
Circulation; 2006 Dec; 114(24):2636-43. PubMed ID: 17145988
[TBL] [Abstract][Full Text] [Related]
4. Economic impact of same-day home discharge after uncomplicated transradial percutaneous coronary intervention and bolus-only abciximab regimen.
Rinfret S; Kennedy WA; Lachaine J; Lemay A; Rodés-Cabau J; Cohen DJ; Costerousse O; Bertrand OF
JACC Cardiovasc Interv; 2010 Oct; 3(10):1011-9. PubMed ID: 20965458
[TBL] [Abstract][Full Text] [Related]
5. Effects of intracoronary compared to intravenous abciximab administration in patients undergoing transradial percutaneous coronary intervention: A sub-analysis of the EASY trial.
Bertrand OF; Rodés-Cabau J; Larose E; Nguyen CM; Déry JP; Proulx G; Roy L; Poirier P; Costerousse O; De Larochellière R
Int J Cardiol; 2009 Aug; 136(2):165-70. PubMed ID: 18656274
[TBL] [Abstract][Full Text] [Related]
6. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication.
Topol EJ; Ferguson JJ; Weisman HF; Tcheng JE; Ellis SG; Kleiman NS; Ivanhoe RJ; Wang AL; Miller DP; Anderson KM; Califf RM
JAMA; 1997 Aug; 278(6):479-84. PubMed ID: 9256222
[TBL] [Abstract][Full Text] [Related]
7. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial.
Thiele H; Schindler K; Friedenberger J; Eitel I; Fürnau G; Grebe E; Erbs S; Linke A; Möbius-Winkler S; Kivelitz D; Schuler G
Circulation; 2008 Jul; 118(1):49-57. PubMed ID: 18559698
[TBL] [Abstract][Full Text] [Related]
8. Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty.
Wöhrle J; Grebe OC; Nusser T; Al-Khayer E; Schaible S; Kochs M; Hombach V; Höher M
Circulation; 2003 Apr; 107(14):1840-3. PubMed ID: 12682003
[TBL] [Abstract][Full Text] [Related]
9. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.
Kastrati A; Mehilli J; Neumann FJ; Dotzer F; ten Berg J; Bollwein H; Graf I; Ibrahim M; Pache J; Seyfarth M; Schühlen H; Dirschinger J; Berger PB; Schömig A;
JAMA; 2006 Apr; 295(13):1531-8. PubMed ID: 16533938
[TBL] [Abstract][Full Text] [Related]
10. Bolus-only platelet glycoprotein IIb-IIIa inhibition during percutaneous coronary intervention.
Marmur JD; Poludasu S; Agarwal A; Vladutiu P; Feit A; Lapin R; Cavusoglu E
J Invasive Cardiol; 2006 Nov; 18(11):521-6. PubMed ID: 17090813
[TBL] [Abstract][Full Text] [Related]
11. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial.
Valgimigli M; Campo G; Percoco G; Bolognese L; Vassanelli C; Colangelo S; de Cesare N; Rodriguez AE; Ferrario M; Moreno R; Piva T; Sheiban I; Pasquetto G; Prati F; Nazzaro MS; Parrinello G; Ferrari R;
JAMA; 2008 Apr; 299(15):1788-99. PubMed ID: 18375998
[TBL] [Abstract][Full Text] [Related]
12. Intracoronary compared to intravenous Abciximab and high-dose bolus compared to standard dose in patients with ST-segment elevation myocardial infarction undergoing transradial primary percutaneous coronary intervention: a two-by-two factorial placebo-controlled randomized study.
Bertrand OF; Rodés-Cabau J; Larose E; Rinfret S; Gaudreault V; Proulx G; Barbeau G; Déry JP; Gleeton O; Manh-Nguyen C; Noël B; Roy L; Costerousse O; De Larochellière R;
Am J Cardiol; 2010 Jun; 105(11):1520-7. PubMed ID: 20494655
[TBL] [Abstract][Full Text] [Related]
13. One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel.
Schömig A; Schmitt C; Dibra A; Mehilli J; Volmer C; Schühlen H; Dirschinger J; Dotzer F; ten Berg JM; Neumann FJ; Berger PB; Kastrati A;
Eur Heart J; 2005 Jul; 26(14):1379-84. PubMed ID: 15734767
[TBL] [Abstract][Full Text] [Related]
14. Long-term mortality after bolus-only administration of abciximab, eptifibatide, or tirofiban during percutaneous coronary intervention.
Marmur JD; Poludasu S; Lazar J; Cavusoglu E
Catheter Cardiovasc Interv; 2009 Feb; 73(2):214-21. PubMed ID: 19156882
[TBL] [Abstract][Full Text] [Related]
15. Aborted myocardial infarction in intracoronary compared with standard intravenous abciximab administration in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction.
Eitel I; Desch S; Schindler K; Fuernau G; Schuler G; Thiele H
Int J Cardiol; 2011 Nov; 153(1):21-5. PubMed ID: 20817283
[TBL] [Abstract][Full Text] [Related]
16. [Does intracoronary abciximab improve the outcome of percutaneous coronary interventions? A randomized controlled trial].
Galache Osuna JG; Sánchez-Rubio J; Calvo I; Diarte JA; Lukic A; Placer LJ
Rev Esp Cardiol; 2006 Jun; 59(6):567-74. PubMed ID: 16790200
[TBL] [Abstract][Full Text] [Related]
17. Treatment synergy of silicon carbide-coated stenting and abciximab for complex coronary artery lesions: clinical results of a single-center study.
van der Vleuten PA; Wijpkema JS; van den Heuvel AF; Bosma CA; Jessurun GA; Tio RA
Ital Heart J; 2004 Sep; 5(9):663-6. PubMed ID: 15568593
[TBL] [Abstract][Full Text] [Related]
18. Comparison of intracoronary vs. intravenous administration of abciximab in coronary stenting.
Kakkar AK; Moustapha A; Hanley HG; Weiss M; Caldito G; Misra P; Reddy PC; Tandon N
Catheter Cardiovasc Interv; 2004 Jan; 61(1):31-4. PubMed ID: 14696156
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial comparing phosphorylcholine-coated stenting with balloon angioplasty as well as abciximab with placebo for restenosis reduction in small coronary arteries.
Hausleiter J; Kastrati A; Mehilli J; Schühlen H; Pache J; Dotzer F; Glatthor C; Siebert S; Dirschinger J; Schömig A;
J Intern Med; 2004 Nov; 256(5):388-97. PubMed ID: 15485474
[TBL] [Abstract][Full Text] [Related]
20. A multicenter randomized study to evaluate intracoronary abciximab with the ClearWay catheter to improve outcomes with Lysis (IC ClearLy): trial study design and rationale.
Sardella G; Sangiorgi GM; Mancone M; Colantonio R; Donahue M; Politi L; Bucciarelli-Ducci C; Carbone I; Francone M; Ligabue G; Fiocchi F; Di Roma A; Benedetti G; Lucisano L; Stio RE; Agati L; Modena MG; Genuini I; Fedele F; Gibson M
J Cardiovasc Med (Hagerstown); 2010 Jul; 11(7):529-35. PubMed ID: 19918189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
